Project Grant R01HL168868
Award Date
7/19/24
Completion Date
5/31/28
Dollars Obligated
$647K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Portland, OR 97239, USA
Similar Awards
This Project Grant award, valued at $402,911.00, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant aims to develop a method for generating a large number of therapeutic nanovesicles (NVs) from mesenchymal stem cells (MSCs) using an extrusion process. These engineered "cell-drones" will be tested for their ability to promote tissue repair in mouse and porcine models of cardiac...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a flexible bioelectronic microarchitecture that integrates a capillary-like delivery network and a tissue-like sensing network to improve cardiac tissue engineering. The $488,026 award supports the creation of a system that can efficiently deliver media and provide real-time physiological feedback to enhance the development of...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $306,102 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Peca Labs Inc. on August 1, 2025. The grant funds the development and feasibility testing of a novel, fully-polymeric, biomimetic prosthetic mitral valve constructed from clinically-proven materials. The goal is to improve durability, performance, and overall outcomes compared to current biologic and mechanical valve options. Specific aims include...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the development of a lesion-targeted nanotherapeutic to address vascular smooth muscle cell (VSMC) dysfunction and mitigate neointimal hyperplasia (NIH), which is a significant issue arising from vascular damage during interventions. The project aims to integrate in vitro transcribed CARMN RNA (a long non-coding RNA critical...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding the development of a novel, injectable biomaterial hydrogel to enable sustained delivery of the therapeutic protein neuregulin-1 (NRG1) to the myocardium for the treatment of myocardial infarction (MI). The $769,789 award to The Leland Stanford Junior University will support a 4-year research project to design and evaluate the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is for the development of an endovascular prosthetic graft device that integrates nitric oxide (NO)-releasing polymer technology. The goal is to create a device that can reduce the incidence of infection, neointimal proliferation, and thrombosis - the three main clinical complications associated with current endovascular stent grafts. The total funding...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $580,863 to Clemson University starting on Dec 23, 2024 to develop engineered human cardiac organoids for heart repair. The project aims to optimize the design of electrically conductive silicon nanowires within the organoids and use pharmacological preconditioning to improve cell survival after implantation. Two sub-awards totaling an unspecified...
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,082,412 to the University of Pittsburgh to optimize and prepare for the manufacturing and regulatory submission of an immunoregulatory tissue-engineered vascular graft (TEVG) device. The key objectives are to: Evaluate the TEVG constructs in vitro using clinically-relevant measures, 2) Validate the performance of scaled-up, human-sized...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas. The grant, effective January 2, 2025 through December 31, 2027, will support the development of microphysiological systems to investigate molecular pathways and cardiomyocyte function in response to hypoxic cardiac injury associated with myocardial infarction and ischemia-reperfusion injury. The project aims to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $256,776 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Irvine (UCI). The objective of this 2-year grant, awarded on August 20, 2024, is to develop novel "metasurface optical guidewires" for therapeutic applications to treat highly stenotic coronary artery calcification (CAC) lesions, which pose significant challenges to successful percutaneous coronary...